Akebia Therapeutics, Inc.AKBAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Akebia Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with kidney diseases, particularly anemia linked to chronic kidney disease. It operates across global markets, focusing on addressing unmet medical needs in the nephrology care segment.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Muneer A. Satter | 8.60% | 16.2M | — | 2024-02-09 |
| BlackRock, Inc. | 7.20% | 15.2M | flat | 2024-11-08 |
| The Vanguard Group | 4.04% | 7.6M | — | 2024-02-13 |
Insider Transactions
Net 90d: +$86.6K · buys $86.6K / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-04 | Butler John P. | CEO and President | Buy (open market) | 69.3K | $1.25 | $86.6K |
1–1 of 1